For decades, drug discovery operated under a simple paradigm: find a small molecule that binds to an enzyme’s active site and blocks its function. This “occupancy-driven” pharmacology works brilliantly for kinases, proteases, and receptors with well-defined binding pockets – but it leaves roughly 80% of the human proteome classified as “undruggable.” Transcription factors, scaffolding proteins, and structural proteins lack the deep binding pockets that traditional inhibitors need to grab onto.
PROTACs – proteolysis-targeting chimeras – represent a fundamental shift in this paradigm. Instead of blocking a protein’s function, PROTACs eliminate the protein entirely by hijacking the cell’s own protein disposal system. The result is a technology that can potentially target proteins that traditional small molecules cannot touch, with a catalytic mechanism that means a single PROTAC molecule can destroy multiple copies of its target protein.
How PROTACs Work: The Molecular Mechanism
A PROTAC molecule is a heterobifunctional compound – it has two functional ends connected by a chemical linker. One end binds to the target protein you want to eliminate (the “warhead”). The other end recruits an E3 ubiquitin ligase, one of the cell’s natural protein-tagging enzymes. The linker holds the two ends at the right distance and orientation to form a productive ternary complex: target protein – PROTAC – E3 ligase, all bound together.
Once this ternary complex forms, the E3 ligase does what it normally does: it attaches ubiquitin chains to the target protein. These ubiquitin chains act as a molecular “death tag” recognized by the 26S proteasome, the cell’s protein shredding machine. The proteasome pulls in the tagged protein, unfolds it, and degrades it into small peptides. The PROTAC molecule, meanwhile, is released intact – free to recruit another copy of the target protein and repeat the cycle.
This catalytic mechanism is one of the key advantages over traditional inhibitors. A conventional inhibitor must be present in sufficient concentration to occupy a large fraction of its target at all times (stoichiometric inhibition). A PROTAC only needs to briefly bring target and E3 ligase together – once ubiquitination occurs, the PROTAC recycles. This means PROTACs can achieve complete target knockdown at sub-stoichiometric concentrations, and their effects persist even after the PROTAC itself has been cleared from the system.
The Three Building Blocks of a PROTAC
1. Target Protein Ligand (Warhead)
The warhead is any molecule that binds to the protein of interest. It does not need to be a potent inhibitor – it just needs to bind. This is a critical distinction: proteins that are resistant to traditional inhibition can still be degraded by PROTACs as long as a binding ligand exists. Even weak binders (micromolar affinity) can serve as effective PROTAC warheads if the resulting ternary complex is productive.
2. E3 Ligase Ligand (Recruiter)
The E3 ligase recruiter is the other functional end of the PROTAC. The choice of E3 ligase profoundly affects degradation efficiency, tissue selectivity, and off-target effects. The four most established E3 ligase systems in PROTAC research are:
Cereblon (CRBN): Recruited by thalidomide-based ligands (pomalidomide, lenalidomide derivatives). CRBN-based PROTACs are the most widely used in the field. Immunomart carries a broad range of CRBN ligands and CRBN-based degraders including dBET1, dBET6, and dBET57 for BET protein degradation research.
Von Hippel-Lindau (VHL): Recruited by hydroxyproline-based ligands. VHL-based PROTACs have shown excellent activity against androgen receptor (AR) and estrogen receptor (ER) targets. Bavdegalutamide (ARV-110), a VHL-recruiting PROTAC targeting the androgen receptor, is among the most advanced degraders in clinical development.
MDM2: Recruited by nutlin derivatives. MDM2-based PROTACs are less commonly used but offer an alternative when CRBN or VHL recruitment is suboptimal.
IAP (Inhibitor of Apoptosis Proteins): Recruited by IAP antagonist/SMAC mimetic ligands. IAP-based PROTACs have shown activity against several kinase targets.
3. Linker
The linker is not merely a passive connector – its length, rigidity, and chemical composition critically influence ternary complex formation, cell permeability, and metabolic stability. PEG-based, alkyl-chain, and rigid aromatic linkers each have distinct properties. Immunomart stocks a comprehensive range of PROTAC building blocks including linker molecules for researchers designing custom degraders.
Why PROTACs Matter for Your Research
PROTACs offer several advantages that make them powerful research tools, even beyond their therapeutic potential:
Complete target elimination vs. partial inhibition: A PROTAC removes the protein entirely – all its functions, including scaffolding and non-enzymatic roles that traditional inhibitors cannot address. This makes PROTACs valuable for studying proteins with complex, multi-functional biology.
Catalytic mechanism: Because PROTACs recycle, they can achieve sustained target knockdown at lower concentrations than traditional inhibitors, reducing off-target effects associated with high compound concentrations.
Overcoming resistance: Target mutations that reduce inhibitor binding often have less impact on PROTAC efficacy, because degradation only requires transient binding rather than sustained occupancy.
Chemical knockdown as an alternative to genetic approaches: PROTACs provide a pharmacological alternative to siRNA or CRISPR for studying the effects of protein depletion, with the advantage of rapid onset (hours vs. days), reversibility, and dose-dependent tunability.
Getting Started with PROTAC Research
For researchers entering the targeted protein degradation field, Immunomart’s PROTAC collection from Targetmol includes ready-to-use degrader compounds targeting BET family proteins, kinases, nuclear receptors, and other validated targets, as well as individual E3 ligase ligands and linker building blocks for designing custom PROTACs. The collection covers CRBN-based, VHL-based, and emerging E3 ligase platforms.
Disclaimer: All products referenced are for laboratory research use only (RUO). Not for human or animal consumption, diagnostic, or therapeutic use. Immunomart supplies research-grade compounds for in vitro and in vivo laboratory studies.
